Quarterly ResultAug 3, 2026, 07:07 AM
Compugen Q2 2026 Revenue $2.6M; Net Loss $7.0M
AI Summary
Compugen Ltd. reported its second quarter 2026 financial results, with revenues increasing to $2.6 million from $1.3 million in the comparable period of 2025, and net loss narrowing to $7.0 million from $7.3 million. The company provided positive updates on its clinical pipeline, including the MAIA-ovarian trial for COM701 progressing as planned with interim analysis data expected by Q1 2027. Partnered programs with AstraZeneca and Gilead also advanced, and Compugen maintains a strong financial position with a cash runway expected to fund operations into 2029.
Key Highlights
- Q2 2026 revenues were $2.6 million, up from $1.3 million in Q2 2025.
- Q2 2026 net loss was $7.0 million, compared to $7.3 million in Q2 2025.
- Q2 2026 basic and diluted net loss per share was $0.07, down from $0.08 in Q2 2025.
- Cash, cash equivalents, short-term bank deposits, and marketable securities totaled $125.3 million as of June 30, 2026.
- Cash runway is expected to fund operations into 2029.
- R&D expenses for Q2 2026 increased to $6.3 million from $5.6 million in Q2 2025.
- MAIA-ovarian trial interim analysis data for COM701 expected by Q1 2027.
- AstraZeneca presented first overall survival readout for rilvegostomig at ASCO 2026.
Price Impact
More from CGEN